A new form of treatment known as CAR-T cell therapy has been making waves in the field of oncology, and clinical trials have begun for patients with Malignant Pleural Mesothelioma (MPM).

A California jury awarded $752 million to Bristol-Myers Squibb over a patent infringement regarding the technology related to a novel cancer therapy.